Cardiometabolic investors have been burned by strong outcomes paired with broken economics. We create the investor and stakeholder narrative that connects your clinical proof, payer traction, and unit economics in one credible story – the story that raises the round and keeps the board aligned between raises.
The Challenge
Your deck presents a clinical story and a growth story that never come together
Cardiometabolic decks usually have a strong outcomes section and a separate growth section, and investors cannot see the bridge between them. They want to know how a great A1C result becomes a payer contract, how that contract becomes durable revenue, and how the unit economics hold as you scale. When the narrative treats clinical proof and commercial traction as two unrelated chapters, sophisticated health investors read it as a company that has not figured out its own model.
Investors have been burned by cardiometabolic outcomes that failed to pay
The category has a history of companies with beautiful clinical data and unsustainable economics – high CAC through clinical channels, adherence that decays, payer contracts that do not renew. Today's cardiometabolic investors carry that scar tissue and screen hard for it. A narrative that leads with outcomes and hand-waves the economics triggers exactly the skepticism you need to disarm, and you lose the room before the meeting is half over.
Your stakeholder groups need distinct stories, but you're giving them the same one
A diabetes company answers to investors, board members, payer partners, and sometimes clinical and regulatory stakeholders – and each weighs different evidence. Investors want scalable economics, payers want trend reduction, the board wants a coherent operating plan. Sending the same generic update to all of them means nobody gets the argument that would actually move them, and misalignment between these groups quietly compounds until a board meeting exposes it.
Between raises, your updates generate anxiety rather than confidence
Cardiometabolic metrics are noisy – enrollment is lumpy through payer and employer channels, and a slow quarter looks alarming without context. Founders who report raw numbers without a narrative that frames trajectory and what they signal end up managing investor anxiety instead of building trust. By the time the next raise comes, the board has been reacting to noise for a year and the relationship is defensive rather than supportive.
How We Support You
We begin with the central narrative challenge: connecting clinical outcomes to durable economics through one story an investor can follow. We create the through-line from a clinical result to a payer contract, then to renewable revenue and unit economics that improve at scale. This is the most important thing a cardiometabolic company can communicate clearly to investors, yet most decks leave it as an unspoken leap of faith. We make that bridge clear and defensible.
Because the category has scar tissue, we shape the narrative to address the particular skepticism cardiometabolic investors bring. We anticipate the CAC-through-clinical-channels question, the adherence-decay question, and the payer-renewal question – not by avoiding them, but by presenting the operating evidence that you have solved or are solving them. Addressing an objection before it comes up is how you earn credibility with an investor who has been burned before.
Next, we create the stakeholder architecture – separate narratives for investors, the board, and payer partners, all derived from one true story. Investors hear the scalable-economics argument, payers receive the trend-reduction case, and the board gets the operating plan. Because each narrative shares the same spine, these groups remain aligned rather than drifting into misalignment that emerges at the worst time. One truth, expressed three ways.
We also establish the between-raises communication rhythm so your updates strengthen confidence instead of creating anxiety. That means giving noisy cardiometabolic metrics the context needed to show trajectory, speaking honestly about slow quarters while clarifying what they signal, and keeping investors in a supportive posture. A consistently informed board supports you through the hard quarter; a reactively managed board does not.
What sets us apart is that we are operators who understand cardiometabolic economics, rather than a PR firm that polishes slides. We develop the narrative from a genuine understanding of how these businesses make money, then connect it to your growth strategy so your investor story reflects the plan you are executing. The result is a fundraising narrative, a deck, and a stakeholder communication system your team can operate.
What we deliver
- Core investor narrative connecting clinical outcomes to durable, scalable economics
- Objection-anticipating story that disarms cardiometabolic investor skepticism
- Stakeholder communication architecture – investor, board, and payer narratives from one spine
- Between-raises update rhythm that frames noisy metrics and builds confidence
- Fundraising deck and messaging aligned to your actual operating plan
Cardiometabolic investors do not question your clinical results – they question whether those results will scale profitably. The winning narrative makes the connection between outcomes and durable economics clear and defensible.
Our Methodology
We work through a focused engagement. The first phase covers diagnosis and narrative: we dig into your clinical evidence, payer traction, and unit economics, then create the core through-line connecting them and the objection-handling needed to disarm category skepticism. The second phase develops the artifacts – the fundraising deck, stakeholder-specific narratives, and between-raises update template – all built from a single story. The last phase focuses on rehearsal and handoff: we pressure-test the narrative against difficult investor questions and prepare your team to manage the communication rhythm.
Unlike a PR or IR agency, we write from an operator's understanding of how cardiometabolic companies actually generate revenue, not from a communications playbook. An agency refines your slides; we repair the argument beneath them and align the investor story with the growth plan you are truly executing, so the two do not conflict during diligence.
The engagement is designed to make you self-sufficient. You own the narrative, deck, and stakeholder system, while your team manages the update rhythm. We would rather give you a strong story and lasting communication capability than serve as a permanent mouthpiece.
Our Working Process
In the first phase, we go deep on the substance – your clinical data, payer contracts, CAC, and retention economics – because a narrative is credible only when it is true. Within the first few weeks, you will have a draft of the core through-line, often marking the first time your clinical and commercial stories have been joined into one argument.
You get a senior operator-communicator who understands cardiometabolic economics. We need direct involvement from your CEO or founder, along with access to your finance and clinical leads, because an investor narrative not owned by the person delivering it will not hold up in a diligence conversation. By nature, this is a leadership-level engagement.
The cadence includes intensive working sessions to develop and pressure-test the narrative, followed by rehearsal against the difficult questions a cardiometabolic investor will raise. We do more than give you a deck – we ensure you can defend every claim it contains and adjust when an investor examines the economics.
Engagements are generally scoped around a fundraise or defined communications need and last two to four months. At the end, you have a fundraising narrative and deck, messaging tailored to each stakeholder, and a between-raises update rhythm managed by your team. Some clients retain us lightly during the raise to make refinements as investor feedback arrives.
- Investor-ready growth narrative
- Reduced diligence friction on economics
- Aligned investor, board, and payer messaging
- Confidence-building update rhythm between raises
If your diabetes & cardiometabolic health company needs investor & stakeholder communications leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
What does an investor communications engagement cost for a cardiometabolic company?
The engagement has a fixed fee based on its scope – typically a fundraise or a defined communications build – and is billed across two to four months. Pricing is well below a banker's fee or the expense of a failed raise, as well as the cost of hiring a full-time head of communications for a one-time need.
How soon will we see results from an investor communications engagement?
You will receive a drafted core narrative in the first few weeks, followed by a fundraising-ready deck and stakeholder messaging within the two-to-four-month engagement window. The final outcome – a completed raise or a board that supports you through a difficult quarter – depends on your market and timing, but you quickly gain the narrative and materials designed to improve those odds.
How does the communications team work with our leadership?
Because this is a leadership-level engagement, we collaborate directly with your CEO or founder, as well as your finance and clinical leads. The person presenting the investor narrative must own it or it will fall apart during diligence, so we develop it alongside you instead of simply delivering a script.
How is Winston Francois different from a conventional PR or IR agency?
A PR or IR agency refines your slides and manages messaging through a communications playbook. We work from an operator's understanding of how cardiometabolic companies actually make money, which means repairing the argument beneath the deck – the connection between clinical outcomes and durable economics – rather than only polishing the language.
How is ROI measured for an investor communications engagement?
The most direct measure is the fundraising outcome – whether the narrative reduces diligence friction around economics and helps close the round on stronger terms. Beyond the raise, we assess stakeholder alignment: whether investors, the board, and payer partners share one coherent story, and whether your between-raises updates keep the board supportive instead of reactive.
How do you address investor skepticism about the cardiometabolic category?
We shape the narrative to address the specific objections these investors bring – high CAC through clinical channels, adherence decay, and payer non-renewal – by raising them directly and presenting the operating evidence that you have addressed or are addressing them. Anticipating the objection builds far more credibility with an investor who has been burned before than leading with outcomes and hoping questions about economics never arise.
What kind of cardiometabolic company is the right fit for this service?
The ideal fit is a Series A through growth-stage diabetes or cardiometabolic company preparing for a raise or managing active board and payer relationships, with genuine clinical and commercial traction to support the narrative. If you do not yet have outcomes or payer evidence, the work is too early – there is not yet a true story to tell.
